References
- Abdelwahed, W., Degobert, G., Stainmesse, S., Fessi, H. (2006). Freeze-drying of nanoparticles: formulation, process, and storage considerations. Adv Drug Deliv Rev 58:1688–1713.
- Bandak, S., Horowitz, D., Horowitz, A., Tzemach, D., Gabizon, A. (1999). Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10:911–920.
- Barnadas-Rodriguéz, R., Sabés, M. (2001). Factors involved in the production of liposomes with a high-pressure homogenizer. Int J Pharm 213:175–186.
- Boulikas, T. (2004). Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12:3–12.
- Carvalho-Junior, A. D. C., Vieira, F. P., Melo, V. J. M., Lopes, M. T. P., Silveira, J. N., Ramaldes, G. A., et al. (2007). Preparation and cytotoxicity of cisplatin-loaded liposomes. Braz J Med Bio Res 40:1149–1157.
- Chen, R. H., Win, H. P., Fang, H. J. (2001). Vesicle size, size distribution, stability, and rheological properties of liposomes coated with water-soluble chitosans of different molecular weights and concentrations. J Liposome Res 11:211–228.
- Cho, K., Wang, X., Nie, S., Chen, Z., Sin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316.
- Cortés-Muñoz, M., Chevalier-Lucia, D., Dumay, E. (2009). Characteristics of submicron emulsions prepared by ultra-high pressure homogenisation: effect of chilled or frozen storage. Food Hydrocoll 23:640–654.
- Crowe, J. H., Carpenter, J. F., Crowe, L. M. (1998). The role of vitrification in anhydrobiosis. Annu Rev Physiol 60:73–103.
- De Oliveira, M. C., Fattal, E., Couvreur, P., Lesieur, P., Bourgaux, C., Ollivon, M., et al. (1998). pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim Biophys Acta 1372:301–310.
- Driscoll, D. F. (2006). Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res 23:1959–1969.
- Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171.
- Franks, F. (1998). Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm 45:221–229.
- Glavas-Dodov, M., Fredo-Kumbaradzi, E., Goracinova, K., Simonoska,M., Calis, S., Trajkovic-Jolevska, S., et al. (2005). The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 291:79–86.
- Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., et al. (2001). Phase I–II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer. Ann Oncol 12:493–496.
- Jenning, V., Lippacher, A., Gohla, S. H. (2002). Medium-scale production of solid lipid nanoparticles (SLN) by high-pressure homogenization. J Microencapsul 19:1–10.
- Júnior, A. D. C., Mota, L. G., Nunan, E. A., Wainstein, A.J.A., Wainstein, A.P.D.L., Leal, AL, et al. (2007). Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Erlich tumor-bearing mice. Life Sci 80:659–664.
- Koster, K. L., Webb, M. S., Bryant, G., Lynch, D. V. (1994). Interactions between soluble sugars and POPC (1-palmitoyl-2-oleoylphosphatidylcholine) during dehydration-vitrification of sugars alters the phase behavior of the phospholipids. Biochim Biophys Acta 1193:143–150.
- Lasic, D. D. (1998). Novel applications of liposomes. Trends Biotechnol 16:307–321.
- Leite, E. A., Giuberti, C. S., Wainstein, A. J., Wainstein, A. P., Coelho,L. G., Lana, A. M., et al. (2009). Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci 84:641–649.
- Mohammed, A. R., Bramwell, V. W., Coombes, A. G. A., Perrie, Y. (2006). Lyophilisation and sterilization of liposomal vaccines to produce stable and sterile products. Methods 40:30–38.
- Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., Amantea,M. A. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating. pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1–7.
- Shi, S., Chen, H., Cui, Y., Tang, X. (2009). Formulation, stability, and degradation kinetics of intravenous cinnarizine lipid emulsion. Int J Pharm 373:147–155.
- Sorgi, F. L., Huang, L. (1996). Large-scale production of DC-Chol cationic liposomes by microfluidization. Int J Pharm 144:131–139.
- Swarbrick, J., Boylan, J. C. (1994). Liposome as pharmaceutical dosage forms. In: Dekker, M., (Ed.), Encyclopedia of pharmaceutical technology, vol 9, (pp 1–39). New York: Informa Healthcare.
- Torchilin, V. P. (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9:128–147.
- Van Winden, E. C. A., Zhang, W., Crommelin, D. J. A. (1997). Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration. Pharm Res 14:1151–1160.
- Wagner, A., Vorauer-Uhl, K., Katinger, H. (2002). Liposomes produced in a pilot scale: production, purification, and efficiency aspects. Eur J Pharm Biopharm 54:213–219.
- Yang, D., Zhu, J., Zheng, Y., Ge, L. (2006). Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes. Drug Dev Ind Pharm 32:219–227.
- Yuan, F, Dellian, M, Fukumura, D, Leunig, M, Berk, DA, Torchilin,VP, et al. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756.
- Zadi, B., Gregoriadis, G. (2000). A novel method for high-yield entrapment of solutes into small liposomes. J Liposome Res 10:73–80.